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Abstract 
5-fluorouracil (5-FU) being a mainstream anticancer drug is under keen and detailed investigation 
for prodrugs formulations in order to minimize the associated side effects. Co-crystallization of 5-
FU is an innovative technique for the synthesis of 5-FU prodrugs to improve its anticancer 
effectiveness. The present study is based on the synthesis of 5-FU supramolecular synthons with 
four co-formers; Succinic acid, cinnamic acid, malic acid and benzoic acid utilizing acetone as a 
solvent. Solid state grinding followed by slow evaporation solution method was applied. Colorless 
clear crystals were obtained in all the cases. The co-crystal formation was supported with the help 
of FTIR and PXRD. Through FTIR, the main peaks of interest in the spectrum of 5-FU, frequency 
(v) of N-H (3409.02 cm-1) and of carbonyl group (1647.80 cm-1), were prominently shifted in all 
the spectra of co-crystal demonstrating the replacement as well as the development of already 
present interactions with new ones. For 5-FU-Cinnamic acid co-crystals, the anticipated peaks 
were observed at 1673.13 cm-1 (–C=O) and 3566.89 cm-1 (N-H) manifesting significant change in 
comparison to 5-FU. With the help of powdered XRD characterization, the representative peak of 
5-FU was recorded at 2θ=28.80o. The shifting of this peak and development of many new ones in 
the spectra of co-crystals proved the development of new structural entities. Finally, the anticancer 
activity of all the co-crystals was evaluated in comparison to that of API. All the co-crystals 
manifest significantly greater growth inhibition potential than the main API. 5-FU-Cinnamic acid 
(3C) was the one which proved to be the most potent anticancer agent at all the four concentrations; 
4.82% (12 μg/mL), 34.21% (25 μg/mL), 55.08 % (50 μg/mL) and 67.29% (100 μg/mL). In short, 
this study proved to be a true example to enhance the anticancer potential of 5-FU following fairly 
easy fabrication requirements of co-crystallization phenomenon. After the successful synthesis of 
these supramolecular synthons and subsequent enhancement of growth inhibition potential of 5-
FU, these co-crystals can further be evaluated for in vivo trials and membrane crossing potentials 
in future.   
Keywords: 5-fluorouracil; co-crystallization; solid state grinding method; MTT assay and 
supramolecular interactions. 
1 Introduction 
5-FU which is simply a uracil derivative is in the exploration of many other biological activities 
in addition to anticancer potential e.g., antimicrobial, anti-fungal, against hypertonic scars, keloids 
and actinic keratosis etc. It is an antimetabolite of uracil obtained by the replacement of hydrogen 
at C-5 of uracil molecule with a fluorine atom, a member of pyrimidine-based antimetabolites. 5-
FU is among the most common chemotherapeutic agents, introduced in 1958 1, used against a 
variety of solid cancers by acting as thymidylate synthase inhibitor e.g., breast, colorectal, gastric, 
head and neck cancers etc. 2, 3. Cancer is not a single disease but a syndrome containing hundreds 
of diseases involving rapid and uncontrolled cell growth with the potential to invade or spread to 
the other parts of the body through the blood circulation. It is a serious public health issue around 
the globe4, 5. The modern mean of cancer therapies, chemotherapy and radiation have, adversarial 
side effects in the individuals suffering from cancer and require much dedication and work to 
minimize the adverse outcomes6. The activity of 5-FU is manifested after several enzymatic 
transformations for its binding to thymidylate synthase and its inhibition, followed by interference 
in the synthesis of nucleic acids 7, 8. Frequent undesirable side effects associated with 5-FU 
chemotherapy are gastrointestinal symptoms, alopecia, cardio-toxicity and neutropenia, while 
leuko-encephalopathy, depression, organic mental disorder 9 have limited its clinical use; only 
tegafur, Floxuridine, Carmofur 10 are potential drugs in use.  
Chemical modification of an active drug in order to minimize its drawbacks and to bring 
unchanged at the targeted site is a contemporary phenomenon to obtain the desired outcomes of a 
drug. In this regard, innumerable approaches for 5-FU structural modifications have been devised 
and tested. 5-FU formulations in the form of nanoparticles 11, 12, 13, 14, 15, combination with 
macromolecules 4, 16, attachment with target selective pro moieties like DNA intercalator 
molecules 17, 18 certainly incorporated and enhanced many vital properties of 5-FU. Following 
these strategies; half-life of 5-FU, target selectivity and sustained blood level is enhanced. 
However; in none of the above-mentioned approaches, synthesis methodologies are free from 
inadequacies. There is not even a single protocol in the above-mentioned strategies which reveals 
combined advantages of single step synthesis, easy synthesis requirements, no need for isolation 
and purification of end products. Co-crystallization is an advanced phenomenon which combined 
all the above-mentioned synthesis requirements in a single methodology19. 
 
5-FU Co-crystals were successfully synthesized with some aromatic compounds; 3-
hydroxybenzoic acid, 4-aminobenzoic acid and cinnamic acid following grinding method. All 
three synthesized co-crystals manifest improved membrane permeability. However, the reasons 
behind the selection of these co-formers were not specified 20. Besides this, cocrystals of 5-FU are 
also reported with heterocyclic compounds; Acridine, Phenazine and 4,4-bispyridylethene 21 and 
benzoic acid derivatives; 4-methylbenzoic acid and 3-aminobenzoic acid following solution 
method. Again in none of these studies, the effectiveness of co-formers was mentioned 22. 
Although, studies are reported about the successful formation of 5-FU co-crystal with a variety of 
co-formers with the help of their structural evidence. However, data is lacking in their biological 
effectiveness; like, in none of these the anticancer potential of the synthesized pro moieties was 
evaluated. In a very recent study, supramolecular synthons of 5-FU were synthesized with two 
dihydroxybenzoic acid compounds (gentisic acid and 3,4-dihydroxybenzoic acid) and a pyridine 
derivative (p-aminopyridine)23. No doubt, the study was comprehensive in lieu of physical and 
biological characterization of synthesized co-crystals. However, ethanol was used as a solvent 
which itself is strongly capable of hydrogen bonding interactions. In a very innovative study of 
drug plus drug co-crystals of 5-FU with 5-fluorocytocine, water was used as a solvent to develop 
co-crystals. Water is itself capable of developing strong hydrogen bonding interactions 24, 25.  In 
short, some of the studies in this domain are focused only on the successful formation of co-crystals 
without their biological evaluation. Also, in majority of the studies the reason behind the selection 
of co-formers or the effectiveness of co-formers is not mentioned. Moreover, the solvents utilized 
for the development of co-crystals in almost all the reported studies are capable of participating in 
the formation of hydrogen bonding interactions. 
 
In contrast to all reported studies; the present study aimed to utilise a solvent not having any 
hydrogen bond donating or accepting groups. 5-FU Co-crystals are being reported with four 
diverse co-formers; cinnamic acid (Cn), succinic acid (Sc), malic acid (Ml) and benzoic acid (Bn). 
All the co-formers were selected by keeping their individual anticancer, antioxidant and anti-
inflammatory properties 26, 27, 28, 29 in consideration which could be resulted in the augmentation of 
the overall effectiveness of 5-FU after co-crystallization. In all the reported studies in this domain, 
methanol or water solvent was used to facilitate the development of supramolecular interactions. 
However, in the present study, acetone, a nonpolar, aprotic solvent is used to ascertain the 
hydrogen bonding interactions only between API and co-formers. Although acetone has partial 
negative oxygen atom and partially positive terminal hydrogens however it does not form 
intramolecular hydrogen bonds however intermolecular hydrogen bonding is reported but only 
with water molecules30.  The co-crystal formation is analyzed with the help of FTIR and PXRD. 
Besides this anticancer potential of all the synthesized co-crystal is evaluated with the help of MTT 
assay. This study is a true example to further develop supramolecular interactions (non-covalent 
interactions) of 5-FU with a variety of effective co formers and further studies can be designed 
following the same approach utilizing a variety of suitable solvents.  
2 Material and methods   
2.1 Materials 
5-FU was purchased by Sigma-Aldrich. Other chemicals in the present study were cinnamic acid 
(VWR, 99%), succinic acid (Avandol, ultrapure), malic acid (BDH Chemicals Ltd, 99.5%), 
benzoic acid (Duksan pure chemicals, 99.5%) and acetone (Merck KGaA, 99.5%). Co-crystals of 
5-FU were synthesized with cinnamic acid, succinic acid, malic acid and benzoic acid following 
solid-state grinding followed by slow evaporation solution method 31,32, 33. 
2.2 Preparation of co-crystals  
2.2.1 Mechanical grinding method  
The equimolar quantities of API (0.572 g) and co-former (Cn, 0.162 g; Sc, 0.129 g; Ml, 0.1474 g 
and Bn, 0.1343 g), 4.4 mM,  were ground strongly using motor and pestle for about 30 minutes. 
The method employed in the study32, was followed with some modifications. The ground mass 
was then dissolved in about 10 mL of acetone to form a solution. Afterwards, it was heated to form 
a clear solution. Finally, the vials were cooled to room temperature and placed for a few days for 
evaporation to observe crystal formation. In all cases, Colourless crystals were obtained. 
2.3 Characterization 
2.3.1 FTIR and PXRD 
The development of supramolecular interactions as a consequence of practical changes in 
vibrational modes of anticipated functional groups were evaluated with the help of FTIR analysis. 
This characterization was done at ATR-FTIR spectrophotometer (Shimadzu IR prestige-21, USA). 
Transmission mode in the range of 400 cm-1 to 4000 cm-1 was applied to record the spectra. The 
study of all the Spectra was done in comparison to the API spectrum alone and the difference 
absorption frequencies of -N-H and -C=O groups from the observed place and shape (position at 
which the peak was observed in the spectrum of API alone) were evaluated in order to study the 
formation of non-covalent interactions for the synthesis of co-crystals 34. For further confirmation 
of new hydrogen bonding interactions, co-crystals were analysed through PXRD 20, 34, 35. PXRD 
analysis is based on constructive interference between homochromatic X-rays and crystalline 
samples. During this procedure, X-rays were formed by cathode ray tube. These rays were then 
filtered to get homochromous rays, accumulated and then focused towards the sample. Finally, the 
bio-evaluation of the as prepared co-crystals was done through MTT assay  36, 37.  
2.3.2 MTT assay In vitro 
For the evaluation of antitumor potential of synthesized co-crystals, Human colorectal cancer cell 
lines (HCT 116) ATCC®CCL-247™ [(catalogue no: 91091005-1VL) Sigma Aldrich] were utilized. 
Cultivation of cells in the form of a monolayer was performed in T-75 flasks Costar and the 
subculturing was done two times a week. The conditions were; 37 oC in CO2 (5%) and 100% 
relative humidity provided incubator. The passage number was kept low, from 5 to 20, for the 
accomplishment of this process. The medium applied for the cultivation of HCT 116 was McCoy's 
5A Gibco Glasgow, complemented with fetal bovine serum (FBS) (10%), Gibco, Glasgow, UK 
and antibiotics (1%) (streptomycin, penicillin)38.  
 
Washing of the anchorage-dependent cells at an exponential growth phase was performed with 
PBS (phosphate buffered saline) about 2 mL. Subsequently, the separation was done with the help 
of 0.5 mL of 1X trypsin and reared for 2–5 minutes at 37 oC in the incubator.  About 100 μL of 
complete growth media was poured into 96-well flat-bottom microplates per well. Afterwards, the 
calculation of cells was performed for anticipated densities with the help of staining using trypan 
blue and tallied with a hemacytometer. Densities of 1,000–100,000 cells per well were injected37. 
Subsequently, cells were treated with a range of concentrations of synthesized co-crystals; 12, 25, 
50 and 100 mg/mL. The experiments were performed in triplicates to avoid errors.  
 
Further in each experiment Background control wells having the same volume of complete culture 
medium were involved accompanied by a positive control comprising Triton X-100 and negative 
controls as well. Then the plate was cultivated at 37 oC for 24 hours in CO2 supplied moistened 
incubator39. 3-(4, 5-dimethyl thiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT) (10 μL) was 
directly supplemented in the culture media of each well after 24 hours. Then incubation of the 
plate was performed for about 4 hours at 37 oC in 5% CO2 incubator. After incubation, the 
separation of culture media was done softly so that the cell`s monolayer remains intact. 
Afterwards, each well was) supplemented with 100 μL volume of dimethyl sulfoxide (DMSO) in 
each well and plate was shaken to homogenize formazan40. Absorbance was evaluated with the 
help of spectrophotometer at 570 nm wavelength. The anticancer potential was found out by the 
calculation of inhibition rate and graphs were plotted against all concentrations. Finally, for each 
extract. IC50 values were calculated. The growth inhibition rate was calculated using Eq. (1) 41: 
 Percentage Mortality (%) = .  (  )  .  (  ) .  (  ) × 100   (1) 
 
where O.D is optical density. 
3 Results and discussion  
3.1 Verification of supramolecular interactions 
This phenomenon is based on the fact, that different chemical bonds and functional groups having 
several vibrational modes absorb in the infrared region and have characteristic absorption peaks. 
FTIR analysis was done to observe the variations in the vibrational modes of functional groups as 
a consequence of new supramolecular interactions. Spectra of co-crystals of API and co- former 
were studied comparatively to the spectrum of API alone and shifting of different peaks such as 
N-H and C=O, from peaks of API spectrum were due to involvement of these groups in hydrogen 
bonding between them. Absorption frequencies of 5-FU, all the co formers and co-crystals are 
represented in Table 1. In the IR spectrum of unsubstituted or non-derivatized 5-FU, a rounded 
peak at 3409.02 cm-1 can be accredited to the absorption frequency of (N-H) group (stretching) 
and a wide sharp band of high intensity at wavenumber, 1647.77 cm-1 can be assigned to v(C=O) 
groups (stretching) 42, 43. 
3.1.1 5-FU-Cinnamic acid (5-FU-Cn) 
For the development of 5-FU supramolecular synthones with Cinnamic acid; the already present 
–N-H…N-H interactions were supposed to be replaced by –N-H…O-H or –N-H…O=C as shown 
in Figure 2. The larger molecule of cinnamic acid is associated with enhanced steric hindrance. 
This leads to weaker supramolecular interactions. These weak intermolecular interactions result in 
strong intramolecular interactions, therefore; it was expected that –N-H groups will absorb at an 
increased stretching frequency. Noninvolvement of molecules in the supramolecular interactions 
are reduced stretching of intramolecular bonds and in turn increase strength. The observation of 
3432.03, 3566.89 cm-1 peaks in the spectrum of co-crystal with a significant blue shift, as clear 
from Figure 1, is supporting the successful synthesis of co-crystals and in an agreement with the 
results of Nadzri et al.,33. This observation is further supported by the shift of -C-N absorption 
frequency towards shorter wavelength (blue shift). In the spectrum of 5-FU, the v (-C-N) was 
observed at 1242.00 cm-1 which shifted hypochromially at 1252.47 in the spectrum of 5-FU-Cn 
supramolecular synthons38. On the other hand, the trend of absorption frequency of -C=O groups 
at 1673.13 cm-1 is according to the trend reported in the literature33 following hypochromic shift. 
Again, the increased strengthening of –C=O bond may be the consequence of increased steric 
hindrance and bigger molecular size of co-former also proposed in Figure 2. This is also proved 
true after the peak at 1179.10 cm-1 (-C-O) 42 in the 5-FU spectrum diminished in the co-crystal 
spectrum due to the vanished single bond properties of carbonyl groups in the course of co-crystal 
formation. 
3.1.2 5-FU-Succinic acid (5-FU-Sc) 
The –N-H absorption frequency for 5-FU-Sc co-crystals was observed at 3543.53 cm-1 clear from 
Figure 4 that manifesting the same blue shift as discussed for the above case exactly in accordance 
with Nadzri et al.,33. Moreover, this observation can also be justified by the same trend of a blue 
shift in the absorption frequencies of -C-N groups; 1346.62cm-1 (5-FU) and 1437.33 cm-1 (5-FU-
Sc)38.  
The absorption frequency of carbonyl groups was observed at 1644.51 cm-1. This frequency seems 
to be almost at the same frequency in comparison to that of un-substituted API and 
bathochromially shifted as compared to the co-former 23 as shown in Figure 3. Moreover, the 
absorption frequencies of -C-O were also observed at almost same positions; 1179.10 cm-1 (5-FU) 
and 1174.75 cm-1 (5-FU-Sc) 42. This suggests the efficient involvement of carbonyl groups of co-
former in the development of hydrogen bonding interaction as compared to 5-FU. This may be the 
result of more steric hindrance of the cyclic structure of 5-FU than the aliphatic structure of 
succinic acid as depicted in Figure 4.  
3.1.3 5-FU-Maleic acid (5-FU-Ml) 
Following the usual hypochromic shift 20, 34, the –N-H absorption frequency of 5-FU-Ml co-
crystals was detected at 3492.20 cm-1, observed from the spectra Figure 5, clearly demonstrating 
the development of new supramolecular interactions as anticipated in Figure 6. As the maleic acid 
has almost the same structure as succinic acid, therefore, a same trend of absorption of carbonyl 
was observed. This frequency of carbonyl groups was recorded at 1669.96 cm-1 (Figure 5); strongly 
red shifted as compared to co-former and reverse is true in comparison to API. This observed trend 
is also affirmed by the observation of -C-O absorption frequencies of API and co-crystals at the 
shift of less than 10 cm-1 (non-significant); 1179.10 cm-1 (5-FU) and 1080.89 cm-1 (5-FU-Ml) 42. 
This suggests the strong disturbance and involvement of carbonyl groups of co-former molecules 
while the very less involvement of carbonyl groups of API in the formation of non-covalent 
interactions between API and Co-former for the development of co-crystals. This could be 
explained by the bigger molecular size of malic acid that generates high steric hindrance while 
forming hydrogen bonds with the consecutive NH-CO-NH groups of 5-FU as manifested in Figure 
6. 
3.1.4 5-FU-Benzoic acid (5-FU-Bn) 
The absorption frequency of –N-H group was observed at 3431.72 cm-1 with regular hypochromic 
shift and the frequency of –C=O was found at 1672.37 cm-1 (Figure 7). The hypochromic shift of 
–N-H group was further tallied with the same shift of -C-N group frequency. Absorption frequency 
of -C-N in the 5-FU spectrum was observed at 1242.00 cm-1 while this group in the co-crystal 
spectrum shown their IR absorption at 1284.12 cm-1 38. On the other hand, the carbonyl group 
frequency of 5-FU at 1647.77 cm-1 is missing in the co-crystal spectrum. As the 1672.37 cm-1 is 
matching with v(C=O) of co-former (1674.98cm-1), therefore; it could be proposed that the double 
bond character of the carbonyl group of 5-FU was diminished as a result of strong involvement of 
this group for the development of supramolecular interactions. Both these frequencies followed 
the same trend as discussed above for all the other co-crystal forms. The proposed hydrogen 
bonding interactions which could be developed are represented in Figure 8. In short, in all the co-
crystal forms, significant shifts in absorption frequencies of anticipated peaks with almost the same 
trends were observed. The observed trends in all the cases are in the favour of an effective 
formation of new non-covalent interactions. 
3.2 Distinction of API and co-crystals` structure by PXRD  
Once the development of supramolecular interactions was clearly recognized through FTIR 
analysis, the formation of co-crystals was supplementarily indorsed with the help of PXRD. The 
intensity, 2θ values, FWHM (full width at half maximum) values of most protruding peaks and 
crystal size of API and all the co-crystals are arranged in Table 2. The values of intensity are 
representative of preferred orientation as well as crystallinity of molecules. FWHM not only 
provides the comparison of data distribution under the curve of most prominent peaks but is also 
important to find out the crystal size. The characteristic peaks in the spectrum of 5-FU are clearly 
different from the respective peaks in the co-crystal spectra in all the above-mentioned aspects as 
well as crystal size. These differences are observable with respect to both the shapes and the 
intensity of the peaks as manifested in Figure 9. These differences are obviously suggestive of the 
changes in the structural properties of API as a consequence of the changes in supramolecular 
interactions with different co-formers 34, 44. 
 
It is observable from the API and co-crystals` stacked graph in Figure 9, the peak observed at 2θ 
=28.80 o, precisely the same as stated in 34, is the most strong representative peak of 5-FU. This 
illustrative value of 5-FU appeared to be prominently different from the values observed in all the 
graphs of co-crystals 23. For 5-FU-Cn co-crystals the most prominent, intense peak appeared at 
27.78o. The intensity of this peak is lesser than the most prominent peak of API manifesting 
decreased preferred orientation and in turn, reduced crystallinity. Similarly, in the case of 5-FU-
Sc co-crystals the intensity of most prominent peak is very low in comparison to that of API 
demonstrating the very small preferred orientation and lessened crystallinity. This finding is also 
supported by the strongest (-N-H) stretching frequencies of 5-FU-Cn and 5-FU-Sc co-crystals with 
the help of FTIR analysis that manifests the strengthening of intramolecular interactions as a 
consequence of weakening of intermolecular interactions as a result of the intervention of co-
former molecules. This resulted in the disturbance of already present supramolecular interactions 
in 5-FU crystal structure due to the development of interactions between 5-FU and co-former 
molecules. Moreover, the crystal size of 5-FU-Sc and 5-FU-Cn co-crystals is smaller than the size 
of API manifesting the formation of co-crystals in the amorphous form 45.   
 
While if we Consider 5-FU-Ml and 5-FU-Bn co-crystals, both have their most prominent peaks at 
28.72 o and almost matching and very high intensities. This observation is revealing much 
enhanced crystallinity as a result of very high preferred orientation. The crystal size of both of 
these co-crystals is much bigger than the 5-FU crystal size. The observation of almost similar peaks 
in 5-FU-Ml and 5-FU-Bn co-crystals may be as a consequence of the same type of groups 
responsible for hydrogen bonding interactions in the same directions. Moreover; the crystal size 
of both the co- formers are almost the same. Besides these facts, there are many other peaks in the 
spectrum of 5-FU which are missing in all the spectra of co-crystals also clear from Figure 9. 
Furthermore, in all the four spectra of co-crystals, many new peaks are found which are indicative 
of the formation of entirely new and different structural entities than 5-FU 34. From all the four co-
crystal forms; 5-FU-Ml and 5-FU-Bn proved to be the entities with the highest crystallinity, having 
bigger crystallite size than the other two co-crystals. 
3.3 Assessment of Anticancer potential of co-crystals through MTT assay 
Table 3 incorporates the values of percent growth inhibition of actinomycetes in vitro at four 
different concentrations in HCT-116 colorectal cell lines, after application of 5-FU alone and all 
the four co-crystals of 5-FU37. For the evaluation of the most effective growth inhibiting agent, 
values are represented comparatively in Figure 10 to Figure 13.  It is clear from the observed values 
that as the concentration of actinomycetes is increased, the value of percent growth inhibition is 
also increased and maximum growth inhibition is observed at 100 ug/mL for API and all the co-
crystals. This trend is quite rational as the increased concentration of actinomycetes provides 
increased substrate sites for the applied agents to execute and subsequently the numerical value of 
growth inhibition is also increased.  
  
After a comparison of all the co-crystals, it is clear that 5-FU-Cn co-crystals proved to be the 
highest growth inhibiting agents at all the four concentrations. At 100 μg/mL concentration, the 
growth inhibiting potential of 5-FU-Cn co-crystals is 67.30%, highest among all the synthesised 
supramolecular synthons. The reason behind this observation may be the anticancer potential of 
cinnamic acid itself. Cinnamic acid derivatives were widely studied and employed as potent 
antitumor agents. The α,β-unsaturated carbonyl moiety in cinnamic acid is considered as an active 
site utilized for the design of anticancer drugs 46. The other most important reason also evident 
from the FTIR and PXRD analysis is the loose bonding (FTIR) and less crystallinity (PXRD) of 
5-FU-Cn co-crystals, resulted in easy release of API and co-former molecules and their prompt 
action. The second most potent anticancer agent as clear from the values of Table 3 are 5-FU-Bn 
co-crystals at all the four concentrations; 66.92% growth inhibition at 100 μg/mL. While the 5-
FU-Ml and 5-FU-Sc cocrystals have mixed trend. However, at 100 μg/mL, 5-FU-Ml acid has 
greater growth inhibition, 44.55% than 5-FU-Sc (38.91%). The reason behind this variable end 
observed for 5-FU-Sc and 5-FU-Ml co-crystals is not clear. Dissimilar growth inhibiting strengths 
of API and all the co-crystals may be attributed to a different structural characteristic of co-formers 
and diverse interactions between API and co-formers. 
4 Conclusion 
Four different co-crystals were synthesized following the solid state grinding followed by normal 
slow evaporation solvent method. The solvent used in this study to facilitate supramolecular 
interactions was acetone; not used before in any study on a similar concept. Co-crystals were 
successfully formed in all four cases at room temperature. FTIR and PXRD analysis of API and 
cocrystals clearly indicated the development of hydrogen bonding interactions between API and 
all the co-formers. In the FTIR spectrum of 5-FU, the absorption frequencies of main anticipated 
peaks that is N-H and –C=O were found at 3409.02 cm-1 and 1647.77 cm-1 respectively. Both of 
these peaks were clearly shifted in all the spectra of co-crystals exactly according to the trends 
reported in the literature. These shifts were clearly indicative of alterations in the intermolecular 
interactions of 5-FU molecules as a consequence of intervention of co-former molecules.  
Moreover, in the PXRD spectrum, the most prominent peak of 5-FU was recorded at 2θ= 28.80. 
This peak was not detected in any spectrum of co-crystals; further, in all the spectra of co-crystals 
many new peaks were recorded manifesting the development of entirely different moieties after 
co-crystallization. After the successful formation of co-crystals in all the four cases, their 
anticancer effectiveness was evaluated utilizing HCT-116 colorectal cell lines at four different 
concentrations of synthesized co-crystals. All the four co-crystals proved to be more effective than 
API alone at all the four concentrations. Moreover, 5-FU-Cn (3C) co-crystals at 100 ug/mL proved 
to be the most potent anticancer agent in this study. In short, this study proved the formation of 
compelling prodrugs of 5-FU following very easy synthesis procedure and conditions. As this 
method is quite captivating from the point of view of its tireless synthesis requirements and diligent 
outcomes; these co-crystals can be further optimized for their in vivo safety. Moreover; many other 
potentially effective co-formers could also be studied in future. 
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List of Tables  
Table 1. FTIR absorption frequencies of the main peaks of interest. 
 
  
Sample ID v (C=O) cm-1 v (N-H) str cm-1 
5-FU 1647.77 3409.02 
5-FU-Cn (3C) 1673.13 3432.03, 3566.89 
Cn (3) 1668.29 - 
5-FU-Sc (4C) 1644.51 3543.53  
Sc (4) 1676.04 - 
5-FU-Ml (5C) 1669.96 3492.20  
Ml (5) 1688.89 - 
5-FU-Bn (6C) 1672.37 3431.72  
Bn (6) 1674.98  - 
 
Table 2. 2θ, FWHM and crystallite size of 5-FU and co-crystals using Scherrer equation. 




Θ θ in 
Radians 
Cos θ FWHM Crystallite 
Size (Aº) 
5-FU 1156 28.80o 14.40 0.25 0.969 0.24 5.96 
5-FU-Cn (3C) 1086.54 27.78o 13.89 0.24 0.971 0.32 4.41 
5-FU-Sc (4C) 787.92 28.78o 14.39 0.25 0.969 0.25 5.79 
5-FU-Ml (5C) 4544.86 28.72o 14.36 0.25 0.969 0.16 8.74 
5-FU-Bn (6C) 4529.28 28.72o 14.36 0.25 0.969 0.17 8.74 
  
 
Table 3. Percentage growth inhibition in HCT-116 cell lines using different concentrations of API 
and Synthesized co-crystals. 
Sample ID Concentrations of actinomycetes 
12 μg/mL 25 μg/mL 50 μg/mL 100 μg/mL 
5FU 7.89±0.64 16.21±0.20 39.53±0.56 54.28±0.56 
3C 24.81±0.42 34.21±0.41 55.08±0.53 67.29±1.73 
4C 14.85±0.57 18.42±0.42 32.89±0.50 38.91±0.51 
5C 9.97±0.90 26.13±0.53 31.02±0.58 44.55±0.57 
6C 23.31±0.58 29.89±0.65 53.57±0.33 66.92±0.63 
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Figure 8. Proposed supramolecular interactions in 5-FU-Bn co-crystals. 
  
 
Figure 9. PXRD spectra of API and co-formers. 



















































Figure 10. Comparison of percentage growth inhibition of 5-FU-Cn co-crystals with 5-FU alone 





































Figure 11. Comparison of percentage growth inhibition of 5-FU-Sc co-crystals with 5-FU alone 




































Figure 12. Comparison of percentage growth inhibition of 5-FU-Ml co-crystals with 5-FU alone 



































Figure 13. Comparison of percentage growth inhibition of 5-FU-Bn co-crystals with 5-FU alone 
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Co-crystallization technique to develop prodrugs of 5-Flourouracil with four organic acids:  
Succinic acid, cinnamic acid, malic acid and benzoic acid was adopted. Characterization and 
anticancer potential of the synthesized crystalline prodrugs were accomplished through FTIR, 
PXRD and MTT assay against HCT-116 colorectal cell lines. All interactions in synthesized 
prodrugs developed following vander walls interactions and exhibited greater cytotoxicity than 5-
Flourouracil. 
 
 
